Trial Profile
Randomized phase II study of vorinostat or placebo in combination with carboplatin and paclitaxel for patients with advanced or metastatic non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2012
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Apr 2011 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center; 2N10-3).
- 23 Nov 2009 Results published in the Journal of Clinical Oncology.
- 04 Aug 2009 Interim results presented at the 13th World Conference on Lung Cancer